Oregon is currently home to 1207 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Kidney and Hypertension Center, Roseburg, Oregon
Conditions: Primary IgA Nephropathy
Register for Updates
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
NCT05680597
Recruiting
This project will determine the feasibility and efficacy of remote assessment and treatment of balance disorders in people with Parkinson's disease.
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/03/2025
Locations: Oregon Health Science University, Portland, Oregon
Conditions: Parkinson Disease
Register for Updates
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
NCT05654506
Recruiting
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Proliferative Glomerulonephritis With Monoclonal IgG Deposits
Register for Updates
Screening Study for Participants With Malignant Tumors
NCT05419375
Recruiting
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Oregon Health Sciences Uni, Portland, Oregon
Conditions: Solid Tumors
Register for Updates
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204
Recruiting
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Oregon Health Sciences Uni, Portland, Oregon
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: Providence St Vincent Med Center, Portland, Oregon
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Cardiogenic Shock Working Group Registry
NCT04682483
Recruiting
The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Providence St. Vincent Heart Clinic, Portland, Oregon
Conditions: Cardiogenic Shock
Register for Updates
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647
Recruiting
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
Gender:
ALL
Ages:
Between 6 years and 100 years
Trial Updated:
06/03/2025
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: Autoimmunity, Inflammation
Register for Updates
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT06773910
Recruiting
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center), Eugene, Oregon
Conditions: Limited Stage Small Cell Lung Cancer
Register for Updates
Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations
NCT06655064
Recruiting
The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time. It will follow subjects and the diagnostic testing and therapy they receive for their prostate cancer. Subjects will not be administered any medical diagnostic testing or therapy that they would not have normally undergone outside of participation in the registry.
Gender:
MALE
Ages:
21 years and above
Trial Updated:
06/02/2025
Locations: Oregon Urologic Institute, Springfield, Oregon
Conditions: Prostate Cancer (Adenocarcinoma)
Register for Updates
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236
Recruiting
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemothe... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Legacy Good Samaritan Medical Center, Portland, Oregon
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
NCT06452316
Recruiting
This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes. The study is comprised of two identical phases (Dosing Phase I and II) of test article dosing separated by a 31- to 40-day period, the Dosing Holiday, where no test article is administered. Dosing Phase II is followed by an observational, noninterventional phase (Observation Phase).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Legacy Devers Eye Institute, Portland, Oregon
Conditions: Limbal Stem Cell Deficiency
Register for Updates